In oncology therapeutics, combining a targeted biologic agent with a second, mechanistically distinct agent can overcome pathway-compensation resistance (e.g., feedback upregulation of a receptor when its downstream effector is blocked), a principle illustrated by triplet versus doublet biologic regimens in BRAF-mutant disease. Circulating tumor DNA (ctDNA) functions as a prognostic and treatment-stratification biomarker, with detectable post-treatment ctDNA indicating minimal residual disease and informing decisions such as adjuvant therapy duration. Immune checkpoint inhibition efficacy is commonly stratified by a combined biomarker score reflecting tumor and immune-cell marker positivity, and its clinical benefit is characterized by a durable-responder pattern in survival curves rather than a uniform treatment effect; separately, clinical fitness for treatment tolerance is a multifactorial construct only partially predicted by chronological age.
In oncology therapeutics, combining a targeted biologic agent with a second, mechanistically distinct agent can overcome pathway-compensation resistance (e.g., feedback upregulation of a receptor whe…